ClinicalTrials.gg
Enrolling by invitationNCT01756222BAVUpdated Oct 20, 2026

Bicuspid Aortic Valve (BAV) Registry

An observational study in Bicuspid Aortic Valve, sponsored by University of Michigan. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Michigan · Observational

How we know

Updated Oct 20, 2026Now Enrolling by invitationGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Bicuspid Aortic Valve Disease with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Bicuspid Aortic Valve Disease · United States.

Planned enrollment
4th of 12
5,000 · median 2,500
Started
2010
the only one that year
Observational
12 of 19
4 open now
Registered
6th of 19
by date
Lead sponsor
3 of 19
University of Michigan

Among the 19 studies in Bicuspid Aortic Valve Disease with a site in United States, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2010, is one of 12 observational ones, and was the 6th registered.

Bicuspid Aortic Valve Disease

62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.

Browse Bicuspid Aortic Valve Disease studies →

Open to participants now

6 of the 19 studies in Bicuspid Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Bicuspid Aortic Valve Disease studies recruiting now, 12 (71%) set no upper age limit and 3 (18%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Bicuspid Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this registry is to gather information on patients with bicuspid aortic valve disease.

Read the detailed description

The purpose of this registry is to gather information on patients with bicuspid aortic valve disease. The data collected in the registry will be used to assess patterns of aortic dilation, responses to medical therapy based on serial imaging and to assess for potential genetic markers of this disease

03

Conditions studied

  • Bicuspid Aortic Valve

Keywords

  • Bicuspid Aortic Valve Disease
  • Bicuspid Aortic Valve
  • BAV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient over the age of 18 who is able/willing to give with the diagnosis of bicuspid aortic valve disease, a family history of this disease or an ascending aortic aneurysm that is idiopathic can be included in the registry.

Exclusion criteria

Exclusion Criteria:

  • Patients unable or unwilling to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
30 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Bicuspid Aortic Valve Disease Patients

    Patients with the diagnosis of BAV disease.

06

What researchers measure

Primary outcomes

  1. Characterizing patients with bicuspid aortic valve disease

    Identifying patients with bicuspid aortic valve disease, assessing the effect of medical intervention.

    Time frame: 30 years

07

Study locations

1 site
  • Univeristy of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2010 (actual). Primary completion is estimated for Dec 2040, 368 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Dec 25, 2012
StartActual
Apr 2010
Primary completionEst.
Dec 2040
CompletionEst.
Dec 2040
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 20, 2026
Contact
No study contact listed any more: removed b•••@med.umich.edu
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Enrolling by invitation
    Contact No study contact listed any more: removed b•••@med.umich.edu
    + 5 other changes: verification date, date precision, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01756222
Responsible party
Dr. Bo Yang (MD, University of Michigan) — Principal investigator
First posted
Dec 25, 2012
Start date
Apr 2010
Primary completion
Dec 2040 (estimated)
Completion
Dec 2040 (estimated)
Last update
Oct 20, 2026

Study contacts

Bo Yang, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion